FNY Investment Advisers’s BioLineRX BLRX Stock Holding History

FNY Investment Advisers’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3	Closed	–	–	719
2018 Q4	$0	Hold	3	–	–	﹤0.01%	701
2018 Q3	$2K	Hold	3	–	–	﹤0.01%	705
2018 Q2	$1K	Buy	+3	New	+$1.59K	﹤0.01%	890

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Delek Group Herzliya, Israel $2.59B AUM 1.24% 1-Year Est. Return

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Susquehanna International Group

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FNY Investment Advisers's BLRX Position: Q1 2019 in Review

FNY Investment Advisers sold out of BioLineRX (BLRX) in Q1 2019, closing a stake of 3 shares.

FNY Investment Advisers first reported a position in BLRX in Q2 2018 and held it in 3 quarters. The position peaked at $2K in Q3 2018. 31 funds tracked by Wall St. Rank hold BLRX as of Q1 2019.

FNY Investment Advisers reported no remaining BioLineRX position as of Q1 2019 after selling out during the quarter.
FNY Investment Advisers sold 3 BioLineRX shares in Q1 2019.
FNY Investment Advisers first reported a position in BioLineRX in Q2 2018 and held it in 3 quarters.
FNY Investment Advisers's BioLineRX position peaked at $2K in Q3 2018.
31 funds tracked by Wall St. Rank held BioLineRX as of Q1 2019.

Based on FNY Investment Advisers's 13F filing for Q1 2019, filed 17 Apr 2019.